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The  S28  serine  peptidase  family  is  something  of  an 
enzymatic  odd  couple.  While  showing  low  sequence 
similarity  to  all  proteins  except  each  other,  the  two 
known family members appear to be at odds functionally; 
one, prolylcarboxypeptidase (PRCP), is a carboxy  pepti­
dase that cleaves single hydrophobic residues from the 
carboxyl termini of proteins that end with a Pro­X motif 
(where X is any hydrophobic amino acid), while the other, 
human  dipeptidyl  peptidase  (DPP7),  is  an  amino  pepti­
dase that cleaves amino­terminal X­Pro dipeptides. The 
structural  basis  of  this  orthogonal  specificity  would 
undoubtedly be interesting, and a recent report in BMC 
Structural  Biology  from  the  Merck  Global  Structural 
Biology  group  (Soisson  et  al.  [1])  has  now  met  that 
expectation. In addition they reveal a new wrinkle to the 
iconic catalytic triad common to most serine hydrolases.
The  practical  pharmaceutical  interest  in  both  these 
enzymes  as  potential  drug  targets  is  at  present  specu­
lative. PRCP can inactivate a number of peptide hormones, 
such as angiotensin II, III and prekallikrein, implicating a 
role for the enzyme in hypertension, tissue proliferation 
and  smooth­muscle  growth.  These  properties  suggest 
that  this  enzyme  may  well  be  a  useful  target  for 
hypertension and anti­inflammatory therapy [2]. Another 
(non­S28  family)  dipeptidyl  dipeptidase  (DPP4)  is  a 
major  drug  target  in  type  2  diabetes,  and  Merck  has 
already  developed  a  successful  inhibitor  of  DPP4,  the 
anti­hyperglycemic drug sitagliptin, for the treatment of 
type 2 diabetes. The DPP enzymes are rich in biological 
functions  and  other  drug  targets  emerging  from  the 
group are possible [3].
A peptidase with a difference
Soisson  et  al.  [1]  have  solved  the  crystal  structure  of 
human  PRCP.  Their  refined  model  reveals  two  major 
domains ­ a prototypical α/β hydrolase fold derived from 
two non­contiguous stretches of the protein and a novel 
helical  bundle  (referred  to  as  an  SKS  domain  by  the 
authors)  that  serves  to  cap  the  active  site.  The  α/β 
hydrolase fold is a tertiary fold adopted by many proteins 
that have no obvious sequence similarity but ultimately 
diverged  from  a  common  ancestor  [4].  In  addition,  a 
dimerization interface is observed that is consistent with 
the  biochemical  properties  of  PRCP  in  solution.  The 
arrangement of the catalytic triad of amino acids in the 
active  site  (Ser179,  Asp430  and  His455)  is  a  classic 
constellation seen in other serine α/β hydrolases [4]. The 
spatial  arrangement  of  these  three  amino  acids  in  the 
active  site  enables  them  to  form  hydrogen  bonds  with 
each  other  and  with  the  substrate  and  cooperate  in 
covalent catalysis by the serine.
The active site does have one surprise ­ an apparent 
charge­relay  system  that  links  the  catalytic  histidine 
(His455) with His456 and Arg460 and might even suggest 
a kind of dual catalytic triad bifurcated off Ser179, the 
ultimate  nucleophile  (Figure  1).  The  function  of  this 
unique system is unknown. The authors suggest that the 
charge  perturbation  of  the  His456/Arg460  diad  may 
explain  the  acidic  pH  optimum  of  PRCP;  that  sounds 
reasonable enough, but some deeper involvement in the 
catalytic mechanism is a tantalizing prospect to ponder. 
A similar adjacent His­His motif, lacking the Arg relay, is 
present in serine lipases [5]. Future work on the function 
of this unique catalytic array will be worth following.
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the carboxyl terminus is explained by the presence of a 
hydrophobic S1 binding pocket, formed by two Met and 
two Trp residues, adjacent to the catalytic serine. This 
appears to be a variation of similar Pro­specific S1 sites 
that  are  found  in  other  prolylpeptidases,  such  as  the 
pharmaceutically important DPP4 [6].
Family comparisons
The structural comparison by Soisson et al. [1] of PRCP 
to  its  family  partner,  the  DPP7  aminopeptidase,  was 
made  possible  by  the  deposition  by  the  Structural 
Genomics Consortium of the coordinates for the struc­
ture of DPP7 in October 2009 (PDB 3JYH); these findings 
have not yet been published. Essentially all of the struc­
tural features observed for PRCP and described above are 
preserved between the two enzymes. With a backbone 
root  mean  square  deviation  (r.m.s.d.)  for  the  aligned 
structures of 1.20 Å, the structural comparison of PRCP 
and  DPP7  described  by  Soisson  et  al.  thus  serves  to 
define a unique fold architecture for the S28 family.
The orthogonality between the PRCP carboxypeptidase 
and the DPP7 aminopeptidase activities is at least partly 
explained by a single peptide insertion sequence in DPP7. 
The resulting disulfide­stabilized, short hairpin structure 
sits in the substrate­binding groove of DPP7, just beyond 
the  proline  S1  binding  site,  blocking  the  binding  of 
substrates beyond the S2 binding pocket (Figure 2). In 
other  words,  the  restricted  binding  groove  can  only 
accom  modate an X­Pro sequence on the amino­terminal 
side  of  the  hydrolytically  sensitive  peptide  bond.  The 
Figure 1. A new charge-relay motif for serine proteases. Part of 
the structure of the active site of PRCP as determined by Soisson et al. 
[1] is shown here. The classic catalytic triad comprises Ser179 (S179), 
His455 (H455) and Asp430 (D430), which are linked by hydrogen 
bonds (H bonds, dotted lines). In the PRCP active site, the catalytic 
H455 is also linked via S179 to H456, which is in turn H-bonded to 
Arg460 (R460). Thus, these five residues form a potential charge-relay 
system. A similar structure is present in DPP7 (PDB 3JYH).
Figure 2. The basis for the orthogonal substrate specificities 
of PRCP and DPP7. PRCP (top) and DPP7 (below), showing the 
substrate-binding groove of PRCP (blue), and the substrate-binding 
site of DPP7 (blue) that is restricted by the hairpin insert (red) [1]. The 
carboxy-terminal side of the catalytic site (see text for discussion) is to 
the left in this illustration.
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dipeptidyl peptidase activity with specificity for proline at 
the  S1  binding  pocket.  The  hairpin  also  introduces  an 
Asp residue, which may be important in binding the free 
amino­terminal amino group of the substrate in the S2 
binding site, in a manner reminiscent of other DPPs, such 
as DPP4.
For PRCP, the absence of the hairpin insert opens up 
the substrate­binding groove for longer amino­terminal 
peptides (Figure 2), thereby loosening substrate specifi­
city towards the carboxyl terminus. It does not, however, 
completely  explain  the  shift  to  the  specific  carboxy­
peptidase activity of PRCP. The binding groove on the 
carboxy­terminal side of the catalytic site appears to be 
open, as in the DPP7 structure (Figure 2), but carboxy­
terminal specificity is restricted to a single amino acid 
beyond the S1 proline, creating an exo­carboxypeptidase. 
It is not immediately obvious why PRCP does not have a 
more pronounced endopeptidase activity. This suggests 
that there are probably other substitutions in the PRCP 
binding groove that restrict the carboxy­terminal peptide 
length. Whatever those substitutions are, they are much 
less  dramatic  than  the  amino­terminal  blockade  that 
creates the DPP7 aminopeptidase specificity.
The  orthogonal  substrate  specificity  noted  for  PRCP 
and DPP7, that is, carboxypeptidase versus aminopepti­
dase activities, suggests a functional discord between the 
pair; this is an illusion. The proline binding at the S1 site 
is  essentially  identical  for  both  enzymes  and  both 
reactions  are  catalytically  superimposable,  with  hydro­
lysis  always  occurring  at  the  proline  carbonyl.  The 
specificity shift appears to be driven by binding forces 
and restrictions that dictate which end of a peptide each 
enzyme  can  accommodate;  the  enzyme  chemistry  for 
both is the same.
As noted earlier, the properties of PRCP might make it 
a potential candidate for a drug target in the treatment of 
hypertension and inflammation. The treatment of hyper­
tension  is  generally  well  served  by  a  large  variety  of 
commercial  drugs,  many  now  generic,  with  different 
mechanisms of action. The bar for the entry of new drugs 
into that space is high; a focus on the anti­inflammatory 
and  cardioprotective  potentials  of  PCRCP  may  be  a 
better approach. Clear evidence of differentiation from 
existing therapies and significant add­on benefit will be 
critical  to  capture  the  developmental  interest  of  major 
pharmaceutical companies. The therapeutic potential of 
DPP7  (also  known  as  DPP2  and  QPP)  is  much  more 
tenuous. Because DPP7 inhibition induces a novel apop­
totic pathway in quiescent lymphocytes, the poten  tial for 
drugs targeting the enzyme in some cancers is interesting, 
albeit  controversial  [7].  In  addition,  tissue­restricted 
deletion of DPP7 leads to metabolic defects, suggesting 
that it may play a novel role in glucose regulation [8]. 
Studies with potent, specific DPP7 inhibi  tors have given 
mixed and, at times, conflicting results [9,10]. Regardless 
of  the  prospects  of  PRCP  and  DPP7  as  viable  drug 
targets,  the  new  insights  into  serine  proteases  gleaned 
from the study of the S28 family will undoubtedly refine 
our molecular understanding of this classic mecha  nism 
of covalent catalysis.
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